Gladius Capital Management LP Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Gladius Capital Management LP bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, HoldingsChannel reports. The institutional investor bought 418 shares of the biopharmaceutical company’s stock, valued at approximately $34,000.

Several other large investors also recently modified their holdings of GILD. Clearbridge Investments LLC grew its stake in Gilead Sciences by 179.0% during the third quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company’s stock worth $340,526,000 after buying an additional 2,915,141 shares in the last quarter. abrdn plc increased its stake in Gilead Sciences by 89.0% in the fourth quarter. abrdn plc now owns 3,764,107 shares of the biopharmaceutical company’s stock valued at $304,930,000 after acquiring an additional 1,772,887 shares during the last quarter. International Assets Investment Management LLC acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $133,584,000. AEGON ASSET MANAGEMENT UK Plc bought a new stake in Gilead Sciences during the fourth quarter worth $63,971,000. Finally, Van ECK Associates Corp boosted its holdings in shares of Gilead Sciences by 18.3% in the 3rd quarter. Van ECK Associates Corp now owns 4,534,839 shares of the biopharmaceutical company’s stock valued at $339,841,000 after purchasing an additional 702,342 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Trading Down 0.5 %

Shares of GILD stock traded down $0.34 on Thursday, hitting $64.58. The company had a trading volume of 6,040,074 shares, compared to its average volume of 7,413,521. The stock’s 50-day moving average is $70.09 and its two-hundred day moving average is $75.52. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.72 and a current ratio of 0.98. The firm has a market cap of $80.41 billion, a P/E ratio of 179.39, a P/E/G ratio of 1.31 and a beta of 0.22. Gilead Sciences, Inc. has a twelve month low of $64.33 and a twelve month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. During the same quarter in the prior year, the firm posted $1.37 EPS. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.77%. Gilead Sciences’s payout ratio is currently 855.56%.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Barclays lowered their price target on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a report on Monday, April 29th. Royal Bank of Canada reduced their price target on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating on the stock in a research note on Friday, April 26th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. Wells Fargo & Company dropped their price objective on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. Finally, Mizuho decreased their target price on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $83.69.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.29% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.